Literature DB >> 30880147

Role of HDACs in cardiac electropathology: Therapeutic implications for atrial fibrillation.

Bianca J J M Brundel1, Jin Li1, Deli Zhang2.   

Abstract

Perpetuation of atrial fibrillation (AF) is caused by electropathology, which is defined as impairment of electrical activation caused by structural and metabolic remodeling of cardiomyocytes. We previously dissected the molecular mechanisms underlying electropathology and identified an important role for histone deacetylases (HDACs). HDACs catalyze the removal of acetyl-groups from lysine residues within nucleosomal histone tails and many non-histone proteins. Various HDAC inhibitors are efficacious in attenuating electropathology, and improve contractile function in experimental AF. Emerging evidence reveals novel mechanisms by which HDAC inhibitors prevent cardiac electropathology and thereby benefit the heart during AF. These mechanisms include post-translational modification of contractile and structural proteins and changes in gene expression. In this review paper, we summarize recent findings on novel functions of zinc-dependent HDACs in electropathology and discuss the potential for pharmacological HDAC inhibition as a strategy to treat AF.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Cytoskeleton; Electropathology; HDACs; Microtubule; Structural remodeling

Mesh:

Substances:

Year:  2019        PMID: 30880147     DOI: 10.1016/j.bbamcr.2019.03.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Res        ISSN: 0167-4889            Impact factor:   4.739


  11 in total

1.  RGFP966 inactivation of the YAP pathway attenuates cardiac dysfunction induced by prolonged hypothermic preservation.

Authors:  Xiao-He Zheng; Lin-Lin Wang; Ming-Zhi Zheng; Jin-Jie Zhong; Ying-Ying Chen; Yue-Liang Shen
Journal:  J Zhejiang Univ Sci B       Date:  2020 Sept.       Impact factor: 3.066

2.  5-Fluoronicotinamide Derivatives as HDAC6 Inhibitors for Treating Heart Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-06-02       Impact factor: 4.632

3.  Nucleoplasmic Ca2+: The 'Mastermind' Behind Pathological Atrial Remodeling?

Authors:  Anna Pfenniger; Shin Yoo; Rishi Arora
Journal:  Circ Res       Date:  2021-03-04       Impact factor: 23.213

Review 4.  Epigenetics in atrial fibrillation: A reappraisal.

Authors:  Rosa Doñate Puertas; Rishi Arora; Sophie Rome; Babken Asatryan; H Llewelyn Roderick; Philippe Chevalier
Journal:  Heart Rhythm       Date:  2021-01-10       Impact factor: 6.779

Review 5.  Epigenetic Mechanism and Therapeutic Implications of Atrial Fibrillation.

Authors:  Dan Li; Jiali Nie; Yu Han; Li Ni
Journal:  Front Cardiovasc Med       Date:  2022-01-21

6.  Sex-dependent transcription of cardiac electrophysiology and links to acetylation modifiers based on the GTEx database.

Authors:  Michael P Pressler; Anelia Horvath; Emilia Entcheva
Journal:  Front Cardiovasc Med       Date:  2022-07-22

7.  Angiotensin receptor-neprilysin inhibitor therapy and recurrence of atrial fibrillation after radiofrequency catheter ablation: A propensity-matched cohort study.

Authors:  Youzheng Dong; Shucai Xiao; Jinwu He; Kaixin Shi; Si Chen; Deping Liu; Bin Huang; Zhenyu Zhai; Juxiang Li
Journal:  Front Cardiovasc Med       Date:  2022-08-04

Review 8.  Multicellular In vitro Models of Cardiac Arrhythmias: Focus on Atrial Fibrillation.

Authors:  Pim R R van Gorp; Serge A Trines; Daniël A Pijnappels; Antoine A F de Vries
Journal:  Front Cardiovasc Med       Date:  2020-03-31

Review 9.  Genetics and Epigenetics of Atrial Fibrillation.

Authors:  Estefanía Lozano-Velasco; Diego Franco; Amelia Aranega; Houria Daimi
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

Review 10.  Human iPSC-Cardiomyocytes as an Experimental Model to Study Epigenetic Modifiers of Electrophysiology.

Authors:  Maria R Pozo; Gantt W Meredith; Emilia Entcheva
Journal:  Cells       Date:  2022-01-07       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.